FG-3019: Phase II started

FibroGen began a double-blind, placebo-controlled, Chinese Phase II trial in up to 144 patients to evaluate thrice-weekly 15 mg/kg IV infusions of FG-3019 for 48 weeks. Patients in the trial will also...